Methods and compositions for targeting PD-L1

US12018015B2 · kind B2 · utility

Assignee

• Aligos Therapeutics, Inc. · US

Inventors

• Tongfei Wu · Leuven, BE
• Pierre Jean-Marie Bernard Raboisson · Sligo, IE
• Francois Gonzalvez · Ekeren, BE
• Antitsa Dimitrova Stoycheva · Rue de l'Église, US
• Cheng Liu · Shanghai, CN
• Jerome Deval · Pacifica, US
• David Craig McGowan · Vilvoorde, BE

Key dates

• Filing date: Jun 15, 2022
• Grant date: Jun 25, 2024
• Expiry date: Jul 25, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.